This is a StreetInsider.com Premium Only Page

Endologix (ELGX) – Press Releases

Mar 19, 2024 07:05 AM PECA Labs Receives Expanded CE Mark for exGraft Family of Vascular Grafts, Allowing for Expandability Designed to Match Growth or Help Avoid Restenosis

Jul 30, 2020 08:00 AM Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System & Official Start of U.S. Commercial Release

Jul 5, 2020 10:35 PM  Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private

Jun 25, 2020 08:00 AM Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires

Jun 23, 2020 07:44 PM DIH Appoints Vaseem Mahboob as Executive Vice President and Chief Financial Officer

Jun 18, 2020 04:30 PM Endologix Announces Departure of CFO and Appointment of Interim CFO

Jun 15, 2020 04:01 PM Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System

May 11, 2020 04:03 PM Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

May 11, 2020 04:01 PM Endologix Reports First Quarter 2020 Financial Results

May 1, 2020 04:01 PM Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020

Apr 14, 2020 04:01 PM Endologix Appoints Tim A. Benner as Chief Commercial Officer

Apr 6, 2020 08:00 AM Endologix Announces Preliminary Financial Results for First Quarter 2020

Mar 30, 2020 08:00 AM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 17, 2020 06:30 PM Endologix Adds Jane E. Kiernan to its Board of Directors

Mar 16, 2020 09:00 AM Endologix Receives FDA Approval for Alto Abdominal Stent Graft System

Mar 6, 2020 08:00 AM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Feb 24, 2020 08:55 AM Endologix Announces Debt Restructuring Addressing 2020 Maturities

Feb 19, 2020 04:01 PM Endologix Reports Fourth Quarter and Fiscal Year 2019 Financial Results

Feb 18, 2020 08:00 AM Endologix, Inc. to Present at the SVB Leerink Global Healthcare Conference

Feb 6, 2020 08:30 AM Endologix Announces Preliminary Financial Results and Conference Call for Fourth Quarter and Full-Year 2019

Feb 3, 2020 08:01 AM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 2, 2020 04:01 PM Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference

Dec 10, 2019 04:01 PM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 11, 2019 04:01 PM Endologix, Inc. to Present at the Stifel Healthcare Conference

Nov 6, 2019 04:01 PM Endologix Reports Third Quarter 2019 Financial Results

Oct 29, 2019 07:01 AM Endologix, Inc. Comments on Recent FDA Update on Type III Endoleaks with AFX® Endovascular AAA System

Oct 24, 2019 04:01 PM Endologix, Inc. to Announce Third Quarter 2019 Financial Results on November 6, 2019

Sep 16, 2019 04:01 PM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 8, 2019 04:05 PM Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

Aug 8, 2019 04:03 PM Endologix Receives IDE Approval for the Nellix Chimney EndoVascular Aneurysm Sealing Protocol

Aug 8, 2019 04:01 PM Endologix Reports Second Quarter 2019 Financial Results

Jul 15, 2019 04:01 PM Endologix, Inc. to Announce Second Quarter 2019 Financial Results on August 8, 2019

Jul 11, 2019 04:01 PM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 17, 2019 04:01 PM Endologix, Inc. to Present at the BMO Prescriptions for Success Healthcare Conference

Jun 6, 2019 04:01 PM Endologix Announces Reinstatement of CE Mark for its Nellix EndoVascular Aneurysm Sealing System

May 2, 2019 04:01 PM Endologix Reports First Quarter 2019 Financial Results

Apr 15, 2019 04:01 PM Endologix, Inc. to Announce First Quarter 2019 Financial Results on May 2, 2019

Apr 1, 2019 07:30 AM Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants

Mar 20, 2019 04:01 PM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 5, 2019 04:01 PM Endologix Announces Approval of Reverse Stock Split

Feb 25, 2019 04:01 PM Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results

Feb 11, 2019 04:01 PM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 29, 2019 04:01 PM Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on February 25, 2019

Jan 22, 2019 04:01 PM Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

Jan 11, 2019 08:00 AM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 10, 2019 08:00 AM Endologix Appoints John D. Zehren as Chief Commercial Officer

Jan 7, 2019 08:00 AM Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance

Jan 4, 2019 08:30 AM Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications

Dec 20, 2018 04:01 PM Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference

Dec 13, 2018 04:01 PM Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)